Genomic Health Shares Up 22.1% After Co. On Sunday Reported TAILORx Which Demonstrated Oncotype DX Breast Recurrence Score Test Definitively Identifies 70% Of Women with Early-Stage Breast Cancer Who Receive No Benefit From Chemotherapy
Benzinga Newsdesk